1. A biologic agent that neutralizes a single cytokine controls one inflammatory disease but fails in another driven by multiple mediators. Integrating the mechanisms of glucocorticoid action, why do glucocorticoids suppress inflammation more completely across diverse diseases than a single-target biologic?
A) They selectively block one dominant cytokine with greater potency than the biologic
B) They act on several arms simultaneously: transcriptional repression of NF-kappaB and AP-1 (activator protein 1) target genes, induction of inhibitory proteins, and post-transcriptional destabilization of cytokine messenger RNA through MKP-1 (MAP kinase phosphatase-1)
C) They physically bind circulating cytokines in the plasma the way a monoclonal antibody does
D) They prevent cytokine receptors from being synthesized while leaving cytokine production intact
E) They work only by inhibiting a single transcription factor, identical in scope to the biologic
ANSWER: B
Rationale:
Glucocorticoids suppress inflammation through several arms acting together rather than one target. Activated glucocorticoid receptor represses NF-kappaB- and AP-1-driven transcription of many inflammatory genes, induces inhibitory proteins such as IkappaB-alpha and annexin-A1, and induces MKP-1, which destabilizes cytokine messenger RNA at the post-transcriptional level. Because they hit initiation, amplification, and message stability at once, they cover diseases driven by multiple mediators that a single-cytokine biologic cannot, making Option B correct.
Option A: Option A is incorrect because the breadth comes from multi-arm coverage, not from blocking one cytokine with superior potency.
Option C: Option C is incorrect because glucocorticoids do not act like a monoclonal antibody binding circulating cytokine; they alter gene expression and message stability.
Option D: Option D is incorrect because they suppress cytokine production rather than selectively blocking receptor synthesis while leaving production intact.
Option E: Option E is incorrect because their scope extends well beyond a single transcription factor, which is precisely why they outperform a narrow-target biologic.
2. A patient with asthma who smokes heavily shows a poor response to inhaled corticosteroids despite good adherence and technique. Applying the cellular mechanism of glucocorticoid action, which explanation and implication best fit?
A) Smoking increases annexin-A1, so the anti-inflammatory pathway is already maximal and the drug adds nothing
B) Smoking accelerates renal clearance of the inhaled drug, so a higher dose will fully restore responsiveness
C) Smoking upregulates glucocorticoid receptors, causing receptor downregulation and tolerance that resolves with a drug holiday
D) Oxidative stress from smoke inactivates histone deacetylase 2 (HDAC2), impairing the receptor's ability to switch off NF-kappaB-driven genes, so cellular corticosteroid responsiveness is reduced and smoking cessation is central to restoring it
E) The drug is fully effective, so the poor response must reflect a non-inflammatory cause unrelated to steroid pharmacology
ANSWER: D
Rationale:
Glucocorticoid suppression of NF-kappaB-driven genes depends in part on the receptor recruiting histone deacetylase 2 (HDAC2) to close chromatin at those promoters. In smokers, oxidative stress modifies and inactivates HDAC2 in airway macrophages, so the receptor cannot effectively recruit functional HDAC2 and corticosteroid responsiveness falls at the cellular level; reducing oxidative stress through smoking cessation is therefore central to restoring response. This makes Option D correct.
Option A: Option A is incorrect because smoke does not maximize annexin-A1 to render the drug superfluous; the defect is at the HDAC2 step.
Option B: Option B is incorrect because the resistance is not explained by accelerated renal clearance, and simply raising the dose does not reliably overcome HDAC2 inactivation.
Option C: Option C is incorrect because the mechanism is HDAC2 inactivation, not receptor upregulation with tolerance reversed by a drug holiday.
Option E: Option E is incorrect because there is a specific steroid-pharmacology explanation for the reduced response rather than it being unrelated to steroid action.
3. A patient started on high-dose systemic glucocorticoids has a complete blood count drawn the next day. Integrating the several cell-specific effects of glucocorticoids, which combined pattern should be expected, and how should it be read?
A) Neutrophilia with lymphopenia, monocytopenia, and eosinopenia together — a predictable redistribution pattern, not evidence of infection, requiring reinterpretation of the usual reference ranges
B) Pancytopenia across all lineages indicating marrow suppression
C) Neutropenia with lymphocytosis indicating an antiviral response
D) Isolated eosinophilia signaling a new allergic process
E) An unchanged differential, since glucocorticoids do not affect circulating leukocytes acutely
ANSWER: A
Rationale:
Glucocorticoids produce a characteristic combined pattern within hours: neutrophilia from demargination and marrow release, lymphopenia from redistribution to lymphoid tissue, monocytopenia from redistribution, and eosinopenia from apoptosis. Read together, this is an expected pharmacological pattern rather than evidence of infection, and it requires reinterpreting the normal reference ranges in a treated patient. This integration makes Option A correct.
Option B: Option B is incorrect because the effect is redistribution producing a specific differential, not pancytopenia from marrow suppression.
Option C: Option C is incorrect because the expected change is neutrophilia with lymphopenia, the opposite of neutropenia with lymphocytosis.
Option D: Option D is incorrect because eosinophils fall rather than rise, so isolated eosinophilia is not expected.
Option E: Option E is incorrect because glucocorticoids change the leukocyte differential markedly within hours, so an unchanged count is not expected.
4. A clinician considers adding an NSAID (non-steroidal anti-inflammatory drug) to a patient already on an adequate anti-inflammatory glucocorticoid dose, expecting an additive reduction in prostaglandin output. Integrating the eicosanoid mechanisms, which assessment is most accurate?
A) The combination doubles leukotriene suppression, providing a large additive benefit
B) The NSAID is essential because glucocorticoids do not affect prostaglandin synthesis at all
C) Because the glucocorticoid already limits arachidonic acid release upstream through annexin-A1 and represses COX-2 transcription, much of the prostaglandin pathway the NSAID targets is already suppressed, so the added prostaglandin-lowering benefit is limited while combined gastrointestinal and other toxicities rise
D) The NSAID will restore leukotriene production that the glucocorticoid suppressed
E) The two agents act at the identical enzymatic step, so the NSAID simply replaces the steroid effect
ANSWER: C
Rationale:
The glucocorticoid already reduces prostaglandin output in two upstream ways: induction of annexin-A1 limits phospholipase A2-mediated release of arachidonic acid, and transcriptional repression reduces inducible COX-2. Because the cyclooxygenase pathway an NSAID targets is already substantially suppressed, the incremental prostaglandin-lowering benefit of adding an NSAID is limited, while the combination raises toxicity risk such as gastrointestinal injury. This integration makes Option C correct.
Option A: Option A is incorrect because NSAIDs do not suppress leukotrienes, so there is no doubling of leukotriene suppression.
Option B: Option B is incorrect because glucocorticoids do reduce prostaglandin synthesis, contrary to the premise that an NSAID is essential for that effect.
Option D: Option D is incorrect because an NSAID does not restore leukotriene production; leukotriene suppression by the steroid arises upstream at phospholipase A2.
Option E: Option E is incorrect because the two classes do not act at the same enzymatic step, so the NSAID does not simply replace the steroid.
5. A kidney transplant recipient on maintenance prednisone and tacrolimus is started on rifampin for a mycobacterial infection. Integrating the metabolic interaction with the immunosuppression strategy, what consequence should be anticipated and monitored?
A) Rifampin will inhibit metabolism and raise immunosuppressant levels, requiring dose reduction to avoid toxicity
B) Rifampin acts only on the glucocorticoid and has no effect on the calcineurin inhibitor, so rejection risk is unchanged
C) Rifampin will have no pharmacokinetic effect because these drugs are renally cleared
D) Rifampin will increase glucocorticoid receptor expression, intensifying immunosuppression and infection risk
E) Rifampin induces CYP3A4 (cytochrome P450 3A4), lowering levels of both the glucocorticoid and the calcineurin inhibitor and thereby raising the risk of acute rejection, so drug levels and allograft function should be monitored closely
ANSWER: E
Rationale:
Rifampin is a potent CYP3A4 inducer. Both the glucocorticoid and the calcineurin inhibitor are metabolized by this pathway, so induction lowers their concentrations and can drop immunosuppression below the threshold needed to prevent alloreactive T cell activation, raising the risk of acute rejection. Close monitoring of drug levels and graft function is therefore required. This integration makes Option E correct.
Option A: Option A is incorrect because rifampin induces rather than inhibits CYP3A4, so levels fall rather than rise.
Option B: Option B is incorrect because the calcineurin inhibitor is also a CYP3A4 substrate, so rejection risk does change.
Option C: Option C is incorrect because these agents undergo CYP3A4 metabolism, so the interaction is pharmacokinetically meaningful rather than absent.
Option D: Option D is incorrect because rifampin lowers glucocorticoid exposure rather than increasing receptor expression and intensifying immunosuppression.
6. Dexamethasone is preferred for cerebral edema and for COVID-19-associated respiratory failure, yet hydrocortisone is preferred for refractory septic shock. Integrating the pharmacological properties with each clinical goal, which explanation best reconciles these choices?
A) Hydrocortisone is more potent than dexamethasone, which is why it is used in the sickest shock patients
B) Dexamethasone's negligible mineralocorticoid activity and long duration suit settings where avoiding fluid retention and giving once-daily dosing are advantageous (cerebral edema, COVID-19), whereas in septic shock the mineralocorticoid activity of hydrocortisone supports vascular tone and its shorter action allows easier titration and discontinuation
C) Dexamethasone has strong mineralocorticoid activity that is desirable in cerebral edema
D) Hydrocortisone has a longer duration than dexamethasone, making it easier to maintain steady levels in shock
E) The agents are interchangeable, and the choice reflects only institutional habit
ANSWER: B
Rationale:
The choices follow from matching drug properties to each goal. In cerebral edema and COVID-19 respiratory failure, dexamethasone's negligible mineralocorticoid activity avoids worsening fluid retention and its long duration allows convenient once-daily dosing. In refractory septic shock, the mineralocorticoid activity of hydrocortisone helps support vascular tone, and its shorter duration makes titration and discontinuation easier as shock resolves. This integration across the three settings makes Option B correct.
Option A: Option A is incorrect because hydrocortisone is less potent than dexamethasone; potency is not the reason it is chosen in shock.
Option C: Option C is incorrect because dexamethasone has negligible, not strong, mineralocorticoid activity, and that absence is part of why it is chosen for edema.
Option D: Option D is incorrect because dexamethasone, not hydrocortisone, is the longer-acting agent.
Option E: Option E is incorrect because the agents differ in mineralocorticoid activity and duration, so the choice is pharmacologically driven rather than arbitrary.
7. A patient on chronic systemic glucocorticoids who previously had a suppressed eosinophil count now shows a rising eosinophil count over serial blood draws. Applying the principle that eosinopenia reflects glucocorticoid receptor engagement, what is the most reasonable inference?
A) The rising eosinophil count suggests the patient is not receiving an adequate active drug effect, prompting evaluation for non-adherence or insufficient dosing
B) The rising count confirms the dose is excessive and should be reduced
C) The rising count proves the drug has become more potent over time
D) The rising count is a normal expected response to ongoing adequate therapy
E) The rising count indicates the glucocorticoid is now fully engaging its receptor
ANSWER: A
Rationale:
A fall in eosinophils is a sensitive marker of active glucocorticoid receptor engagement. When a previously suppressed eosinophil count rises in a patient who should be therapeutically suppressed, the most reasonable inference is that adequate drug effect is no longer being delivered, which warrants evaluation for non-adherence or inadequate dosing. This application makes Option A correct.
Option B: Option B is incorrect because a rising eosinophil count signals too little effect, not an excessive dose.
Option C: Option C is incorrect because the trend points to reduced, not increased, drug effect.
Option D: Option D is incorrect because under adequate ongoing therapy the eosinophil count should remain suppressed rather than rise.
Option E: Option E is incorrect because full receptor engagement would keep eosinophils low, so a rising count indicates the opposite.
8. A patient is beginning prolonged high-dose glucocorticoid therapy. Integrating the effects on the RANKL/OPG (receptor activator of nuclear factor kappa-B ligand / osteoprotegerin) system and on osteoblasts, which prediction about bone and the rationale for prophylaxis is correct?
A) Bone formation will increase because glucocorticoids stimulate osteoblast proliferation
B) Bone mass will remain stable because increased resorption is matched by increased formation
C) Only resorption is affected, so therapy targeting osteoblasts would be useless
D) Net bone loss is expected because glucocorticoids raise RANKL and lower OPG to favor osteoclast-driven resorption while simultaneously suppressing osteoblast differentiation and promoting osteoblast apoptosis, which makes early anti-resorptive prophylaxis mechanistically rational
E) Bone turnover halts entirely, so no intervention is needed
ANSWER: D
Rationale:
Glucocorticoids increase RANKL and decrease OPG, shifting the balance toward osteoclast differentiation and bone resorption, and at the same time they suppress osteoblast differentiation and promote osteoblast apoptosis, reducing formation. The combination of increased resorption and decreased formation predicts net bone loss, which is why early anti-resorptive prophylaxis is mechanistically rational in patients starting prolonged high-dose therapy. This integration makes Option D correct.
Option A: Option A is incorrect because osteoblast differentiation is suppressed and apoptosis promoted, so formation falls rather than rises.
Option B: Option B is incorrect because formation does not rise to match resorption; the two move in opposite, bone-losing directions.
Option C: Option C is incorrect because both resorption and formation are affected, so the osteoblast arm is clinically relevant.
Option E: Option E is incorrect because turnover is not halted; resorption is actively favored, producing ongoing loss.
9. Two patients with comparable chronic glucocorticoid exposure are scheduled for procedures: one for a minor procedure under regional anesthesia, the other for major abdominal surgery under general anesthesia. Applying the principle that the cortisol stress response scales with operative magnitude, how should perioperative coverage differ?
A) Both should receive identical high-dose stress coverage because both are surgeries
B) Neither requires any change to the usual dose regardless of procedure type
C) The minor regional-anesthesia procedure requires little or no supplementation beyond the usual dose, while the major abdominal procedure under general anesthesia warrants full stress-dose hydrocortisone coverage proportional to the larger expected cortisol surge
D) The minor procedure requires more coverage because regional anesthesia blocks all cortisol release
E) The major surgery needs less coverage because general anesthesia suppresses the stress response entirely
ANSWER: C
Rationale:
The normal cortisol response is proportional to operative magnitude: minor procedures, especially under regional anesthesia, evoke little cortisol elevation, whereas major abdominal surgery under general anesthesia produces a large, sustained surge. Coverage should therefore scale accordingly, with little or no supplementation for the minor procedure and full stress-dose hydrocortisone for the major one. This application makes Option C correct.
Option A: Option A is incorrect because identical high-dose coverage over-treats the minor procedure, ignoring the graded response.
Option B: Option B is incorrect because the major procedure does require supplementation in a patient with presumed suppression.
Option D: Option D is incorrect because regional anesthesia attenuates but does not abolish the response, and minor procedures need less, not more, coverage.
Option E: Option E is incorrect because general anesthesia for major surgery is associated with a large cortisol surge rather than complete suppression of the stress response.
10. A patient with HPA (hypothalamic-pituitary-adrenal) axis suppression from chronic glucocorticoid therapy develops adrenal insufficiency. Integrating the difference between secondary and primary adrenal insufficiency, which electrolyte pattern is expected and why?
A) Hyperkalemia with hyponatremia, because mineralocorticoid output is lost as in primary adrenal insufficiency
B) Hyperkalemia with hypernatremia, reflecting aldosterone excess
C) Hypokalemia with hypernatremia, reflecting mineralocorticoid excess
D) Normal sodium and potassium, because adrenal insufficiency never alters electrolytes
E) Hyponatremia without hyperkalemia, because suppression of the HPA axis reduces glucocorticoid output while the renin-angiotensin-aldosterone-driven mineralocorticoid axis is largely preserved
ANSWER: E
Rationale:
In secondary adrenal insufficiency from HPA axis suppression, glucocorticoid output falls but the mineralocorticoid axis, driven mainly by renin-angiotensin-aldosterone rather than ACTH, is largely preserved. The result is hyponatremia (partly from impaired free-water handling) without the hyperkalemia that characterizes primary adrenal insufficiency, where aldosterone is also lost. This integration makes Option E correct.
Option A: Option A is incorrect because hyperkalemia reflects mineralocorticoid deficiency seen in primary, not secondary, adrenal insufficiency.
Option B: Option B is incorrect because aldosterone excess is not the situation, and hypernatremia is not expected.
Option C: Option C is incorrect because mineralocorticoid excess is not present in this glucocorticoid-deficient state.
Option D: Option D is incorrect because adrenal insufficiency can produce hyponatremia, so electrolytes are not necessarily normal.
11. The systemic safety of inhaled corticosteroids depends on a pharmacokinetic dissociation, but this protection is not unlimited. Applying that principle to a patient on high-dose fluticasone propionate for severe asthma, which expectation is correct?
A) High-dose inhaled therapy carries no systemic risk because the first-pass effect is absolute at any dose
B) At high doses (for example fluticasone propionate above approximately 500 micrograms per day or equivalent), the inhaled fraction reaching the systemic circulation becomes large enough to cause measurable systemic effects such as HPA (hypothalamic-pituitary-adrenal) axis suppression, posterior subcapsular cataracts, and skin thinning, so the lowest effective dose with regular review is advised
C) High-dose inhaled therapy produces more systemic effect than equivalent oral therapy because inhalation bypasses metabolism entirely
D) Systemic effects appear only if the patient swallows the entire dose rather than inhaling it
E) High-dose inhaled corticosteroids cannot suppress the HPA axis under any circumstances
ANSWER: B
Rationale:
The favorable local-to-systemic ratio of inhaled corticosteroids comes from poor gastrointestinal absorption of the swallowed fraction and extensive first-pass metabolism, but the inhaled fraction that reaches the circulation directly is not eliminated by first-pass metabolism. At high doses this systemically available fraction grows enough to cause measurable effects, including HPA axis suppression, posterior subcapsular cataracts, and skin thinning, which is why the lowest effective dose with regular review is recommended. This application makes Option B correct.
Option A: Option A is incorrect because the first-pass effect is not absolute and does not remove the directly absorbed inhaled fraction, so systemic risk rises with dose.
Option C: Option C is incorrect because inhaled therapy generally produces less, not more, systemic effect than equivalent oral therapy.
Option D: Option D is incorrect because systemic effects arise mainly from the inhaled fraction reaching the circulation, not solely from swallowed drug.
Option E: Option E is incorrect because high-dose inhaled corticosteroids can in fact suppress the HPA axis.
12. A patient on long-term systemic glucocorticoids is at heightened risk for certain infections. Integrating the effects on macrophages and cell-mediated immunity, which infection pattern and mechanism best fit?
A) Increased susceptibility to intracellular and opportunistic pathogens, because suppression of the M1 macrophage phenotype reduces respiratory burst, phagocytosis, MHC (major histocompatibility complex) class II antigen presentation, and IL-12 (interleukin-12), impairing the cell-mediated immunity that controls these organisms
B) Increased susceptibility only to extracellular bacteria, with cell-mediated immunity fully intact
C) No change in infection risk, since glucocorticoids enhance macrophage killing
D) Selective protection against intracellular pathogens due to macrophage activation
E) Risk limited to allergic reactions rather than infection
ANSWER: A
Rationale:
Glucocorticoids suppress the classically activated (M1) macrophage phenotype, reducing the respiratory burst, phagocytosis, MHC class II-dependent antigen presentation, and IL-12 production, and they impair dendritic cell priming of T cells. Because cell-mediated immunity controls intracellular and opportunistic organisms, this suppression predicts increased susceptibility to such infections. This integration makes Option A correct.
Option B: Option B is incorrect because cell-mediated immunity is impaired rather than intact, so risk is not limited to extracellular bacteria.
Option C: Option C is incorrect because macrophage killing is reduced, not enhanced, so infection risk rises.
Option D: Option D is incorrect because macrophages are suppressed rather than activated, so there is no selective protection against intracellular pathogens.
Option E: Option E is incorrect because the predominant concern is infection from impaired cell-mediated immunity, not merely allergic reactions.
13. In a patient with bacterial meningitis, antibiotics are given first and adjunctive dexamethasone is added only the next day. Applying the mechanistic rationale for dexamethasone timing in meningitis, what is the most likely consequence?
A) The delayed dexamethasone will still provide its full neuroprotective benefit because timing does not matter
B) The delayed dexamethasone will worsen outcomes by directly promoting bacterial growth
C) The delayed dexamethasone will improve antibiotic penetration into the cerebrospinal fluid
D) Much of the protective benefit is likely lost, because the major inflammatory surge from antibiotic-induced bacterial lysis has already occurred and dexamethasone needed to be present with or before the first antibiotic dose to blunt it
E) The delayed dexamethasone will have no effect on inflammation at any point in the illness
ANSWER: D
Rationale:
Adjunctive dexamethasone reduces severe neurological sequelae by blunting the intense subarachnoid inflammatory response triggered when antibiotics lyse bacteria. That benefit depends on the drug being present with or immediately before the first antibiotic dose. If it is given a day later, the major lysis-driven inflammatory surge has already occurred, so much of the protective benefit is likely lost. This application makes Option D correct.
Option A: Option A is incorrect because timing is central to the benefit, so a delayed dose does not provide full neuroprotection.
Option B: Option B is incorrect because dexamethasone does not directly promote bacterial growth.
Option C: Option C is incorrect because the rationale concerns suppressing the inflammatory surge, not improving antibiotic penetration into cerebrospinal fluid.
Option E: Option E is incorrect because dexamethasone does modulate inflammation; the issue is that the critical window for the protective effect has passed.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.